发布求助
文献互助 智能选刊 最新文献

Clinical Advances in Hematology & Oncology最新文献

筛选
英文 中文
The use of genomic assays to guide chemotherapy in breast cancer. 使用基因组分析来指导乳腺癌化疗。
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Kevin M Kalinsky
{"title":"The use of genomic assays to guide chemotherapy in breast cancer.","authors":"Kevin M Kalinsky","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6","pages":"379-380"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anaphylactic reactions to blood transfusions: focus on alpha-gal syndrome. 输血过敏反应：关注α -半乳糖综合征。
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Colleen Gilstad
{"title":"Anaphylactic reactions to blood transfusions: focus on alpha-gal syndrome.","authors":"Colleen Gilstad","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6","pages":"381-383"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fruquintinib as third-line therapy in mCRC without targetable mutations, insights from the FRESCO and FRESCO-2 trials: switching mechanism of action in a patient experiencing significant toxicity on chemotherapy. fruquininib作为无靶向突变mCRC的三线治疗，FRESCO和FRESCO-2试验的见解：在化疗毒性显著的患者中转换作用机制
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Tanios S Bekaii-Saab
{"title":"Fruquintinib as third-line therapy in mCRC without targetable mutations, insights from the FRESCO and FRESCO-2 trials: switching mechanism of action in a patient experiencing significant toxicity on chemotherapy.","authors":"Tanios S Bekaii-Saab","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6 Suppl 7","pages":"1-12"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association. 重新定义复发/难治性多发性骨髓瘤的二线治疗策略、测序和现实世界的实施：来自第31届欧洲血液学协会年会上的见解
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Ajai Chari, Peter M Voorhees, Raymond Thertulien
{"title":"Redefining second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: insights from the 31st Annual Congress of the European Hematology Association.","authors":"Ajai Chari, Peter M Voorhees, Raymond Thertulien","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The management of relapsed/refractory (R/R) multiple myeloma (MM) continues to evolve with the introduction of novel therapies and the use of newer therapies in different treatment settings and combinations. Chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA) and bispecific antibodies targeting BCMA and GPRC5D were initially introduced in the heavily pretreated R/R MM setting but have now demonstrated efficacy benefits in earlier lines of therapy. Encouraging results have recently been reported from 3 major phase 3 trials-MonumenTAL-3, MajesTEC-3, and MajesTEC-9-showing significant progression-free survival (PFS) as well as confirmed or preliminary overall survival (OS) improvements with bispecific-containing regimens over current standard-of-care triplets. Bispecific antibodies are associated with a risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) and on-target, off-tumor toxicities, including infections and hypogammaglobulinemia with BCMA-targeting agents and oral and skin-related toxicities with GPRC5D-targeting agents. Implementation of bispecific antibodies requires proactive monitoring and management by a knowledgeable and prepared interdisciplinary team. Treatment selection is individualized based on disease-related factors, treatment history, and patient-related factors and preferences. Adoption of bispecific antibodies in community-based oncology practices will be essential for maximizing the benefit of these therapies and ensuring they reach the patients in need.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6 Suppl 8","pages":"1-14"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practical approach to second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: Q&A. 复发/难治性多发性骨髓瘤二线治疗策略、测序和现实世界实施的实用方法：问答。
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Ajai Chari, Peter M Voorhees, Raymond Thertulien
{"title":"Practical approach to second-line treatment strategy, sequencing, and real-world implementation in relapsed/refractory multiple myeloma: Q&A.","authors":"Ajai Chari, Peter M Voorhees, Raymond Thertulien","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6 Suppl 8","pages":"10-13"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining second-line strategy after MonumenTAL-3, MajesTEC-3, and MajesTEC-9 (presented at the EHA 2026 Congress). 继MonumenTAL-3、MajesTEC-3和MajesTEC-9（在EHA 2026大会上提出）之后，重新定义二线战略。
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Peter M Voorhees
{"title":"Redefining second-line strategy after MonumenTAL-3, MajesTEC-3, and MajesTEC-9 (presented at the EHA 2026 Congress).","authors":"Peter M Voorhees","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6 Suppl 8","pages":"4-7"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant therapies in high-risk localized prostate cancer: past, present, and future. 高危局限性前列腺癌的新辅助治疗：过去、现在和未来。
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Sonam Saxena, Jake O'Hara, Qilin Cao, Bruce Haik, Ji Whae Choi, Christopher Koller, Michael D Stifelman, Nitin Yerram
{"title":"Neoadjuvant therapies in high-risk localized prostate cancer: past, present, and future.","authors":"Sonam Saxena, Jake O'Hara, Qilin Cao, Bruce Haik, Ji Whae Choi, Christopher Koller, Michael D Stifelman, Nitin Yerram","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Treatment for high-risk localized prostate cancer can be particularly challenging because of an elevated risk of disease recurrence. One of the proposed ways to improve the success of definitive localized treatment (such as radical prostatectomy or radiation therapy) for these patients is the addition of neoadjuvant therapy. Thus, therapeutic strategies that have demonstrated benefit in metastatic prostate cancer settings have been translated to and evaluated in the neoadjuvant setting. The therapies studied include androgen deprivation therapy, ranging from androgen receptor-specific blockade to more comprehensive androgen signaling pathway blockade; chemotherapy, especially taxane-based therapy; immunotherapy; and most recently, prostate-specific membrane antigen radioligand therapy. In this review, we provide an overview of various trials that have explored the pathologic and oncologic results of these therapies in various prostate cancer settings and discuss the emerging role of theranostics in this space.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6","pages":"353-361"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relapsed/refractory multiple myeloma: disease overview and treatment landscape. 复发/难治性多发性骨髓瘤：疾病概述和治疗前景。
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Ajai Chari
{"title":"Relapsed/refractory multiple myeloma: disease overview and treatment landscape.","authors":"Ajai Chari","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6 Suppl 8","pages":"2-4"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GVHD prophylaxis for patients undergoing stem cell transplant. 干细胞移植患者的GVHD预防。
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Piyanuch Kongtim
{"title":"GVHD prophylaxis for patients undergoing stem cell transplant.","authors":"Piyanuch Kongtim","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6","pages":"362-364"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world adoption of bispecific antibodies in the community and outpatient settings: insights from OPTec and OPTal (presented at the ASCO Annual Meeting 2026). 社区和门诊双特异性抗体的实际应用：来自OPTec和OPTal的见解（在2026年ASCO年会上发表）。
IF 2
Clinical Advances in Hematology & Oncology Pub Date : 2026-09-01
Raymond Thertulien
{"title":"Real-world adoption of bispecific antibodies in the community and outpatient settings: insights from OPTec and OPTal (presented at the ASCO Annual Meeting 2026).","authors":"Raymond Thertulien","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 6 Suppl 8","pages":"8-9"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148984270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书